{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:54Z","timestamp":1791912474606,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006310","name":"Swedish Medical Research Council","doi-asserted-by":"crossref","award":["2014-3077"],"award-info":[{"award-number":["2014-3077"]}],"id":[{"id":"10.13039\/501100006310","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.nmd.2017.03.007","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T19:06:46Z","timestamp":1489691206000},"page":"565-568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab"],"prefix":"10.1016","volume":"27","author":[{"given":"Dagur Ingi","family":"Jonsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritva","family":"Pirskanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2017.03.007_bib0010","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2017.03.007_bib0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2017.03.007_bib0020","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2017.03.007_bib0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2017.03.007_bib0030","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2017.03.007_bib0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-016-1108-9","article-title":"Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials","volume":"18","author":"Teitsma","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nmd.2017.03.007_bib0040","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nmd.2017.03.007_bib0045","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2017.03.007_bib0050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2017.03.007_bib0055","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1212\/01.WNL.0000163988.28892.79","article-title":"Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2017.03.007_bib0060","doi-asserted-by":"crossref","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nmd.2017.03.007_bib0065","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1084\/jem.20130699","article-title":"MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies","volume":"210","author":"Molnarfi","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2017.03.007_bib0070","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2017.03.007_bib0075","first-page":"625","article-title":"Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial","volume":"34","author":"Kremer","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nmd.2017.03.007_bib0080","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/rheumatology\/kev372","article-title":"ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany","volume":"55","author":"Iking-Konert","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2017.03.007_bib0085","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3899\/jrheum.141210","article-title":"Long term safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2017.03.007_bib0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","article-title":"Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial","volume":"388","author":"Bijlsma","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2017.03.007_bib0095","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3109\/s10165-012-0782-y","article-title":"Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis","volume":"23","author":"Kojima","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.nmd.2017.03.007_bib0100","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1352458511418631","article-title":"Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis","volume":"18","author":"Nielsen","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.nmd.2017.03.007_bib0105","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896617300512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896617300512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:06:04Z","timestamp":1760774764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896617300512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0960896617300512"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2017.03.007","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2017.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}